AstraZeneca Says Obesity Pill Well-Tolerated and Competitive (2)

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

The oral treatment resulted in patients losing an average of 5.8% of their body weight over four weeks in an early study, the UK pharma company reported at the ObesityWeek conference in San Antonio, Texas. There was a “dose dependent increase in nausea and vomiting,” as can be expected with this type of drug, said Sharon Barr, executive vice-president of biopharmaceuticals R&D.

Astra’s shares were down 0.3% in early trading Tuesday ...